Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-022049
Filing Date
2022-08-11
Accepted
2022-08-11 15:11:01
Documents
54
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 798862
2 ex31-1.htm EX-31.1 17470
3 ex31-2.htm EX-31.2 17501
4 ex32.htm EX-32 7934
  Complete submission text file 0001493152-22-022049.txt   3326963

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pvct-20220630.xsd EX-101.SCH 26588
6 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pvct-20220630_cal.xml EX-101.CAL 45717
7 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pvct-20220630_def.xml EX-101.DEF 104560
8 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pvct-20220630_lab.xml EX-101.LAB 219170
9 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pvct-20220630_pre.xml EX-101.PRE 175675
48 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 381995
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 221155305
SIC: 2834 Pharmaceutical Preparations